Lynx Dx’s Post

🔬 Exciting Advances in Metastatic Kidney Cancer Research: Unveiling Key Markers for Survival 🚀 I'm thrilled to share insights from a recent study published in our Special Issue at Biomedicines (IF= 4.7, Q1 in pharmacy and pharmacology), where I am the guest editor. This research was on advanced metastatic renal cell carcinoma (mRCC), shedding light on crucial markers that could influence survival rates. In the analysis of 55 mRCC patients undergoing first-line treatment with sunitinib, the researchers delved into clinical, pathohistological, and molecular data, focusing on the expression of Receptor Interacting Protein 5 (RIP5) and Vestigial Like Family Member 4 (VGLL4). 🔍 Key Findings: RIP5 Expression Trends: The authors observed a fascinating linear increase in RIP5 protein expression with tumor-grade progression. Notably, 80% of RIP5-positive cells were found in high-grade mRCC and control kidneys, whereas grade 2 mRCC exhibited significantly lower RIP5 expression (5.63%). VGLL4 Expression Trends: Conversely, the expression of VGLL4 displayed a linear decrease as the tumor grade advanced. The highest protein expression of VGLL4 was recorded in grade 2 (87.82%), compared to grades 3 and 4, as well as the control group. Survival Correlations: High mRNA expression of RIP5 correlated with longer first-line overall survival and progression-free survival in mRCC patients. Additionally, elevated VGLL4 mRNA expression was associated with improved overall survival in patients with clear cell renal cell carcinoma (ccRCC). 📈 Implications for Clinical Practice: These findings suggest that monitoring the mRNA expression of RIP5 and VGLL4 could serve as valuable prognostic markers for mRCC patients. The observed correlations with survival rates highlight their potential as indicators of treatment response and overall patient outcomes. 🌐 Future Directions: To explore the therapeutic implications of these molecular markers and their potential for personalized treatment strategies in the mRCC. Link of the full-text: https://lnkd.in/g5mPYWWR #MedicalResearch #mRCC #CancerResearch #PrecisionMedicine #ScienceAdvances #OncologyResearch

Bruce Levine and Carl June weigh in on the FDA investigation into secondary T-cell cancers post CAR-T treatment. Despite the FDA probe, the experts affirm that the benefits of CAR-T therapies far outweigh potential risks in the majority of cases. The Nature Medicine Comment emphasizes the importance of continuing to offer commercial CAR-T products based on up-to-date safety information. Read the full article here: https://lnkd.in/g7cxEkAa Link to Nature Medicine Comment: https://lnkd.in/giRZ7_xz #OCBio, #OrangeCountyBio, #CGT, #CellandGeneTh

A new breakthrough platform will enable non-invasive clinical assays in time for clinical decision. The “Rapid, Reproducible, Rare Cell 3D Expansion” (R3CE) is able to generate solid tumors, rare cells, Circulating-Tumor-Cells (CTCs) and more. This opportunity will allow physicians to accurately predict drug resistance acquired over treatment cycles. It was developed by Dr. Mark D Pegram, Dr. Ying C Chang, Dr. Wen-Hung Kuo, Dr. Yu Zong, Dr. Yen-Jang Huang, and Dr. Jia-Yang Chen. Read more about the R3CE’s capabilities here ⬇️ https://lnkd.in/gsyY4YMY

In venture capital people talk about how an individual deal needs to return a fund. Accounting for the losses and driving the overall return profile required for investors. In DeepTech, this requirement translates as a very large market opportunity, where incumbents can't innovate because they lack the competitive talent moats required to develop new approaches to a particular problem space. Its not often that you find companies that fit this mould, but when they announce results like QV Bioelectronics have today you start to believe you might just have found one. Empirical Ventures is actively looking for syndication partners for this deal, please get in touch if you would like an intro to Christopher Bullock. https://lnkd.in/e_dB69Qn

AI and personalized cancer medicine - useful insights in this new publications by Gabrièle Breda ProductLife Group -In 2021 alone, more than 100 applications received by the US FDA included some aspects of AI -AI supports decision making and therapy planning as well as in early multi-cancer precision diagnostics -Other applications include drug companion apps, and "Digital twins" -> What challenges ahead and what needs to be done to support broader and faster adoption of this type of innovation? -> What is a digital twin and what regulatory framework is associated? #futureofpharma #accesstomedicine #AI #aiinhealthcare https://lnkd.in/e5d3s6jd

I am guest editing a Special Issue of @IJMS_MDPI on "Cardioprotection in Drug-induced Cardiotoxicity" and would welcome the submission of papers in this area. Details of the call can be found here: #Cardiotoxicity #Cardioprotection #Cardiooncology #CancerReseach

🔬 Discover the new value framework for NGS in Europe, focusing on key criteria and stakeholder consensus. This framework will guide the effective implementation of NGS, ensuring it meets the needs of the healthcare community. #SyenzaNews #PrecisionMedicine #ValueAssessment #NextGenerationSequencing #ValueFramework #EuropeanOncology 📊 Join the conversation on advancing precision medicine in European oncology. Share your insights on improving access to NGS/CGP diagnostics! https://lnkd.in/dEnx-ES8

In this week's edition of Vault's Healthcare Weekly Wrap-Up, check out the significant advances in obesity drug trials, partnerships for cancer diagnostics, major funding rounds for oncology therapies, and innovations in AI and wearable technologies aimed at enhancing patient care. Key developments also touch on legal and regulatory challenges facing the sector, including drug approval milestones and the ongoing impact of supply chain issues. #Healthcare #Innovation #Oncology #AIinHealthcare #PharmaNews #WearableTech For a comprehensive overview of the latest news and its implications for healthcare professionals and investors 👇👇

 🚀 More Exciting News from QV Bioelectronics! 🚀 We're thrilled to announce breakthrough pre-clinical safety and efficacy results for our revolutionary Glioblastoma therapy! 💼 Now Raising Series A Investment: Join us as we aim to deliver longer, better quality lives for brain tumour patients. 🌟 Key Highlights: Successful Large Animal Studies: Proven safety of our novel Electrical Field Therapy (EFT) stimulation for up to three months with no significant adverse events. Robust Efficacy: Our proprietary stimulation methodology outperforms industry leaders, showing remarkable effectiveness against advanced patient-derived GBM models. FDA Milestone: Positive feedback from the FDA on our validation plan, significantly de-risking the pathway to first-in-human trials. As the creators of the world’s first implantable EFT device targeting Glioblastoma (GBM), the most aggressive primary brain cancer in adults, we are pioneering a new era in cancer treatment. With a market worth over $30 billion and the potential to dramatically improve patient outcomes, our innovative technology is set to disrupt the space currently dominated by a single incumbent. 🔬 Our latest data highlights major successes at the preclinical stage, and we're excited to continue advancing towards clinical trials For more detail read our press release below 🔗 (Disclaimer: Product in pre-clinical development and has not yet received market approval from medical device regulatory agencies)